^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herzuma (trastuzumab-pkrb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity
Published date:
11/08/2022
Excerpt:
...the in-vivo study using HER2-low breast cancer PDTX model showed that the NK therapy in combination with Herzuma® and paclitaxel group significantly inhibited the tumor growth as compared to combined Herzuma® and paclitaxel group or control (p=0.003, vs control; p=0.01, vs Herzuma® + paclitaxel).
Secondary therapy:
paclitaxel
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0886
